// App-Quantinova.ai

4533 : Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).

Researchers

Presenter

  • Jonathan E. Rosenberg

Principal Investigators

  • Elisabeth I. Heath

  • Peter J. Van Veldhuizen

  • Jaime R. Merchan

  • Joshua Michael Lang

  • Joseph D. Ruether

  • Daniel Peter Petrylak

  • Randeep S. Sangha

  • David C. Smith

  • Srikala S. Sridhar

  • Elaina M. Gartner

  • Martha Vincent

  • Rong Chu

  • Banmeet Anand

  • Fernando Donate

  • Lynnae Jackson

  • Leonard M. Reyno

  • Jingsong Zhang

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • University of Kansas Medical Center, Westwood, KS

  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Yale University, New Haven, CT

  • Cross Cancer Institute, Edmonton, AB, Canada

  • University of Michigan, Ann Arbor, MI

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Seattle Genetics, Bothell, WA

  • Agensys Inc, Santa Monica, CA

  • Agensys Inc, Santa Monica, CA

  • Agensys Inc, Santa Monica, CA

  • Agensys Inc, Santa Monica, CA

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

  • Canada

Companies

  • Agensys, Inc. (Astel

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • Nectin Cell Adhesion Molecule 4

Drug/Treatment

  • Enfortumab vedotin

  • Cisplatin

  • ASG-22CE

Outcome

  • Unknown

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02091999

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved